[Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon]

X Amiot; J D Grangé; F Boudghene; D Lamarque; J P Lotz; V Izrael; F Bodin

[Prolonged partial remission of a hepatocellular carcinoma treated with adriamycin and recombinant human alpha-2 interferon]

Ann Gastroenterol Hepatol (Paris). 1991 Oct;27(5):211-4.

[Article in French]

Authors

X Amiot¹, J D Grangé, F Boudghene, D Lamarque, J P Lotz, V Izrael, F Bodin

Affiliation

¹ Service d'Hépatogastroentérologie, Hôpital Tenon, Paris.

PMID: 1660687

Abstract

Adriamycin is one of the chemotherapeutic agent often administered in the treatment of unresectable hepatocellular carcinoma. On monotherapy, the reported rate response is between 0 to 15 p. cent, without improvement on survival. Its combination with other cytotoxic molecules, such as interferon, has been suggested to improve the percentage of response rates. We present the case of a 73 years old man, who underwent a prolonged partial response of a hepatocellular carcinoma with adriamycin and recombinant human interferon alpha-2.

Publication types

Case Reports

MeSH terms

Aged
Alcoholism / complications*
Carcinoma, Hepatocellular / diagnostic imaging
Carcinoma, Hepatocellular / etiology
Carcinoma, Hepatocellular / therapy*
Combined Modality Therapy
Doxorubicin / administration & dosage
Doxorubicin / therapeutic use*
Humans
Interferon Type I / administration & dosage
Interferon Type I / therapeutic use*
Liver Neoplasms / diagnostic imaging
Liver Neoplasms / etiology
Liver Neoplasms / therapy*
Male
Recombinant Proteins
Remission Induction / methods*
Tomography, X-Ray Computed

Substances

Interferon Type I
Recombinant Proteins
Doxorubicin